Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 4

Hypertonic Saline for MAC

NCT04921943 · View on ClinicalTrials.gov ↗

Study Summary

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Interventions

  • DRUG Azithromycin
  • DRUG Hypertonic saline
  • DRUG Ethambutol
  • DRUG Rifampin

Study Locations (3)

New York

  • NYU Langone Health — New York

Oregon

  • Oregon Health & Science University — Portland

Ontario

  • University Health Network — Toronto

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-05-18
Est. Completion 2025-12-31
Phase Phase 4

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04921943

The ClinicalTrials.gov registry entry for NCT04921943 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 665 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Nontuberculous Mycobacterial Lung Disease appearing as the primary indexed condition, and to 4 interventions — of which Azithromycin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04921943 reports 3 study locations spanning 3 distinct geographic areas — top geographies include New York, Oregon, Ontario. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04921943 about?

NCT04921943 is a clinical study titled "Hypertonic Saline for MAC". The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

What is the current status of trial NCT04921943?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-05-18. Estimated completion is 2025-12-31.

What conditions does trial NCT04921943 study?

This clinical trial studies the following conditions: Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04921943?

The interventions under investigation include: Azithromycin (DRUG), Hypertonic saline (DRUG), Ethambutol (DRUG), Rifampin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04921943?

This trial is sponsored by Oregon Health and Science University, which has 665 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04921943 being conducted?

This trial has 3 study locations across New York, Oregon, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial